177 related articles for article (PubMed ID: 26553684)
1. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
Sow SO; Okoko BJ; Diallo A; Viviani S; Borrow R; Carlone G; Tapia M; Akinsola AK; Arduin P; Findlow H; Elie C; Haidara FC; Adegbola RA; Diop D; Parulekar V; Chaumont J; Martellet L; Diallo F; Idoko OT; Tang Y; Plikaytis BD; Kulkarni PS; Marchetti E; LaForce FM; Preziosi MP
N Engl J Med; 2011 Jun; 364(24):2293-304. PubMed ID: 21675889
[TBL] [Abstract][Full Text] [Related]
3. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC
Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688
[TBL] [Abstract][Full Text] [Related]
4. Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.
Tang Y; Plikaytis BD; Preziosi MP; Borrow R
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S531-9. PubMed ID: 26553685
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
[TBL] [Abstract][Full Text] [Related]
6. Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Tapia MD; Findlow H; Idoko OT; Preziosi MP; Kulkarni PS; Enwere GC; Elie C; Parulekar V; Sow SO; Haidara FC; Diallo F; Doumbia M; Akinsola AK; Adegbola RA; Kampmann B; Chaumont J; Martellet L; Marchetti E; Viviani S; Tang Y; Plikaytis BD; LaForce FM; Carlone G; Borrow R
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S514-20. PubMed ID: 26553683
[TBL] [Abstract][Full Text] [Related]
7. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
[TBL] [Abstract][Full Text] [Related]
9. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
[TBL] [Abstract][Full Text] [Related]
10. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
[TBL] [Abstract][Full Text] [Related]
12. Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
Holme D; Findlow H; Sow SO; Idoko OT; Preziosi MP; Carlone G; Plikaytis BD; Borrow R
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S563-9. PubMed ID: 26553689
[TBL] [Abstract][Full Text] [Related]
13. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
14. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
[TBL] [Abstract][Full Text] [Related]
15. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S; Njanpop Lafourcade BM; Ouangraoua S; Ouoba A; Kpoda H; Findlow H; Tall H; Seanehia J; Martin C; Ouedraogo JB; Gessner B; Meda N; Borrow R; Trotter C; Mueller JE
Clin Infect Dis; 2019 Jan; 68(3):435-443. PubMed ID: 30481265
[TBL] [Abstract][Full Text] [Related]
16. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
[TBL] [Abstract][Full Text] [Related]
17. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M
Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt.
Sundaram ME; Wolfson J; Osterholm M; Sow S; Ansah PO; Diallo A; Cusick SE
Vaccine; 2020 Dec; 38(52):8351-8356. PubMed ID: 33223309
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
Tapia MD; Sow SO; Haidara FC; Diallo F; Doumbia M; Enwere GC; Paranjape G; Hervé J; Bouma E; Parulekar V; Martellet L; Chaumont J; Plikaytis BD; Tang Y; Kulkarni PS; Hartmann K; Preziosi MP
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S507-13. PubMed ID: 26553682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
